News & Events
Find a Person
Dr. Philip Halloran
Director of the Alberta Transplant Applied Genomics Centre
Molecular Microscope™ System
Cell Culture, Immunology and Clinical Core
Computational Biology and Biostatistics Core
Kidney Transplant MMDx™ System
Konrad Famulski, PhD
Anna Hutton, BSc
Cell Culture, Immunology & Clinical
Luis Hidalgo, PhD
Computational Biology & Biostatistics
Jeff Reeve, PhD
Konrad Famulski, PhD
Clinical & Post Doctoral Fellows
Dina Badr, MB BCh, MSc
Katelynn Madill-Thomsen, BSc.
The Alberta Transplant Applied Genomics Centre (ATAGC) is a
core service facility
with multidisciplinary expertise spanning the areas of applied genomics, pathology, molecular biology, immunology, biostatistics and experimental design. In addition to our research, we provide advice and services to other researchers at the University of Alberta and elsewhere.
Our mission is:
To improve human health care by applying molecular understanding to human disease, and specifically by studying the molecular changes in human tissue biopsies
Our goals are
To develop our understanding of disease phenotypes and mechanisms.
To reclassify disease states and outcomes.
To intervene effectively to prevent progressive organ failure in transplants and in primary organ diseases.
The ATAGC is led by Dr. Philip Halloran,
a renowned clinical and research nephrologist, and was established by a Genome Canada grant along with investments from the Faculty of Medicine & Dentistry, Alberta Health Services, Canada Foundation for Innovation, Alberta Advanced Education and Technology, and several pharmaceutical and biotechnology companies.
What we do:
he ATAGC examines the
molecular phenotype of disease states
in humans and relevant animal models in relationship to conventional
phenotyping like histopathology and diagnostic imaging.
Biopsies from patien
ts with organ disease are the principal point where the molecular phenotype meets the conventional phenotype.
We take a
to explore the molecular basis of disease phenotypes. We have analyzed thousands of biopsy samples from humans and animals using high
throughput gene expression technology like microarrays, histopathology, antibody studies and outcomes.
Our current focus is on organ transplants such as kidney, heart, liver and lung; however, we are successfully applying insights to
primary organ diseases
. Biopsies of diseases such as hepatitis C, inflammatory bowel diseases, heart and lung diseases, progressive renal disease, skin diseases and cancer are very instructive.
Email & Apps
University of Alberta